Gallium-68 DOTATOC PET/CT In Vivo Characterization of Somatostatin Receptor Expression in the Prostate-Reference-Cited by-同舟云学术

Gallium-68 DOTATOC PET/CT In Vivo Characterization of Somatostatin Receptor Expression in the Prostate

Published:2014-04 Issue:3 Volume:29 Page:108-115
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Todorović-Tirnanić Mila V.¹²,Gajić Milan M.³,Obradović Vladimir B.¹²,Baum Richard P.⁴

Affiliation:

1. Faculty of Medicine, University of Belgrade, Serbia.

2. Center for Nuclear Medicine, Clinical Center of Serbia, Serbia.

3. Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Serbia.

4. Department of Nuclear Medicine, Centre for PET/CT, Bad Berka, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2013.1570

Reference33 articles.

1. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

2. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives

3. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SSTR-based theranostics in neuroendocrine prostate cancer (NEPC);Clinical and Translational Imaging;2022-12-12

2. Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT;Cancers;2022-12-08

3. A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer;Cancers;2022-09-01

4. Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review;Journal of Clinical Medicine;2021-10-24

5. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer;Pharmaceuticals;2020-03-05